scholarly journals Hearing Screening of Newborns using Distortion Product Otoacoustic Emissions

2021 ◽  
Vol 29 (2) ◽  
pp. 189-195
Author(s):  
Vybhavi MK ◽  
Srinivas V
Keyword(s):  
Hearing Loss ◽  
Otoacoustic Emissions ◽  
Screening Tool ◽  
Hearing Screening ◽  
Distortion Product Otoacoustic Emissions ◽  
Profound Hearing Loss ◽  
Distortion Product ◽  
Lost To Follow Up ◽  
Evoked Response Audiometry

Introduction  The present study was devised to estimate the prevalence of neonatal hearing loss and document the importance of using DPOAE as a screening tool for identifying hearing loss in newborns. Materials and Methods This hospital based descriptive study was conducted from August 2018 to August 2019. A total of 928 newborn babies were included in the study. These newborn babies were subjected to hearing screening by distortion product otoacoustic emissions (DPOAE) at 24-72 hrs after birth. For pass cases, no further testing was done. For refer cases, repeat testing with DPOAE was done within 15-30 days. Newborns with refer result on repeat DPOAE testing were subjected to Brainstem evoked response audiometry (BERA) within 3 months to confirm hearing loss. Results Nine hundred and twenty eight newborn babies were screened by DPOAE. 851 newborns passed the first DPOAE hearing screening and 77 newborns gave refer result. 21 newborns were lost to follow-up. 56 newborns underwent repeat DPOAE testing and 5 newborns were referred for BERA. Amongst the 5 newborns who underwent BERA testing, one newborn was diagnosed with bilateral profound hearing loss. Hence, the prevalence of hearing loss of 1.08 per thousand newborn babies was estimated in this study. Conclusion Hearing screening of newborns using DPOAE followed by BERA in refer cases to confirm hearing loss is useful for early detection followed by timely intervention and rehabilitation.

scholarly journals Finding out incidence of deafness among neonates at a tertiary care centre of western Rajasthan, India using otoacoustic emission

2019 ◽  
Vol 6 (2) ◽  
pp. 338
Author(s):  
Ashish Gupta ◽  
Vinod Kumar
Keyword(s):  
Hearing Loss ◽  
Otoacoustic Emissions ◽  
Large Scale ◽  
Tertiary Care ◽  
Screening Method ◽  
Hearing Screening ◽  
Distortion Product Otoacoustic Emissions ◽  
Research Association ◽  
Screening Programs ◽  
Distortion Product

Background: Newborn hearing screening is conducted to identify suspected hearing loss and not to confirm the presence/absence of hearing loss or define features of the loss. Speech and hearing are interrelated, i.e., a problem with one could mean a problem with the other as speech and language is acquired normally through auditory system.Methods: A descriptive study conducted in the Department of Paediatrics, Dr. S. N. Medical College, Jodhpur, from June 2016 to December 2017. 5000 neonates were screened using otoacoustic emissions (OAE) in 2 stages at birth during 3rd to 7th day and 15-30 days respectively, followed by BERA at 3 months of age.Results: 1.4 infants per thousand infants had hearing loss. Presence of high-risk factors was seen to be associated be associated with hearing loss more than normal infants on screening with distortion product otoacoustic emissions (DPOAE) tests. However, on testing with BERA no such association was seen.Conclusions: 1.4 per 1000 infants had hearing loss. This study has shown that two stage distortion product otoacoustic emissions (DPOAE) hearing screening followed by british educational research association  (BERA) to confirm the hearing deficit, can be successfully implemented as new born hearing screening method in a hospital set-up, for early detection of hearing impaired, on a large scale, to achieve the high-quality standard of screening programs in a resource limited and developing nation like India.

scholarly journals Application of otoacoustic emissions and brainstem evoked response audiometry in newborn hearing screening

2021 ◽  
Vol 8 (1) ◽  
pp. 26
Author(s):  
Gangadhara K. S. ◽  
Amrutha V. Bhat ◽  
Sridhara S.
Keyword(s):  
Hearing Loss ◽  
Otoacoustic Emissions ◽  
Screening Tool ◽  
Hearing Screening ◽  
Evoked Response ◽  
Care Hospital ◽  
Newborn Hearing Screening ◽  
Brainstem Evoked Response Audiometry ◽  
Newborn Hearing ◽  
Evoked Response Audiometry

<p class="abstract"><strong>Background: </strong>Newborn hearing screening was conducted in a tertiary care hospital in a step by step manner using otoacoustic emissions (OAE) and brainstem evoked response audiometry (BERA) and details were recorded.</p><p class="abstract"><strong>Methods:</strong> A prospective institutional based study was conducted. All the newborns born in the hospital over a period of 18 months from December 2018 to May 2020 were considered in the study. Healthy newborns were screened bedside within 24 hours of delivery and NICU (Neonatal Intensive Care Unit) babies were screened in the NICU. Handheld OAE apparatus was used as the initial screening tool. A total of 3 OAEs were done for babies with a “refer” result in the OAEs, which were done 1 month apart. Babies with a “refer” in the third OAE were subjected for BERA.</p><p class="abstract"><strong>Results:</strong> A total of 14226 babies were screened at 24-48 hours of birth. Among them, 13,069 babies passed the first OAE screening in both ears. Remaining babies were referred for further follow-up. After subsequent follow-ups and successive testing, 11 babies were found to have hearing loss, which was diagnosed within 4-5 months of the child’s birth.</p><p class="abstract"><strong>Conclusions: </strong>Universal newborn hearing screening is the need of the day. OAE is an effective screening tool for newborn hearing loss. When complemented by BERA, majority of congenitally deaf babies can be diagnosed at a very early age. This helps in early intervention.</p>

Relationship Between Distortion Product Otoacoustic Emissions and Hearing Loss

2006 ◽  
Vol 2 (1) ◽  
pp. 2-9
Author(s):  
Tiffany A. Johnson ◽  
Stephen T. Neely ◽  
Michael P. Gorga
Keyword(s):  
Hearing Loss ◽  
Otoacoustic Emissions ◽  
Distortion Product Otoacoustic Emissions ◽  
Distortion Product

Hearing Screening of High-Risk Newborns with Brainstem Auditory Evoked Potentials: A Follow-up Study

PEDIATRICS ◽  
1984 ◽  
Vol 73 (1) ◽  
pp. 22-26 ◽  
Author(s):  
Dorothy A. Shannon ◽  
Jacob K. Felix ◽  
Allan Krumholz ◽  
Phillip J. Goldstein ◽  
Kenneth C. Harris
Keyword(s):  
Hearing Loss ◽  
High Risk ◽  
Predictive Value ◽  
Screening Test ◽  
Normal Hearing ◽  
Hearing Screening ◽  
Auditory Evoked Potential ◽  
Hearing Level ◽  
Lost To Follow Up

Numerous techniques have been used in attempts to find a reliable and efficient screening method for determining auditory function in the newborn. The brainstem auditory evoked potential (BAEP) is the latest method advocated for that purpose. The BAEP was evaluated as a hearing screening test in 168 high-risk newborns between 35 and 45 weeks of conceptual age. Follow-up data were obtained after 1 year (mean 17.3 months) on 134 of the infants (80%). Normal hearing was defined as a reproducible response in both ears to a 25 dB normal hearing level (nHL) click stimulus; 21 infants (12.5%) failed the initial screening test. Follow-up on 19/21 infants revealed 18 infants with normal hearing and one infant with an 80 dB nHL bilateral hearing loss substantiated. One infant with an abnormal screening test died before retesting, and the other infant was lost to follow-up but had only a unilaterally abnormal BAEP. None of the infants with a normal BAEP screening study had evidence of hearing loss on retesting. Sensitivity of the BAEP was 100%, specificity was 86%, predictive value of a positive test was 5.26%, and the predictive value of a negative test was 100%. The incidence of significant hearing loss in our population was between 0.75% (1/134 infants) confirmed, and 2.24% (3/134 infants) including infants who failed screening but were lost to follow-up. The BAEP is a sensitive procedure for the early identification of hearing-impaired newborns. However, the yield of significant hearing abnormalities was less than predicted in other studies using BAEP for newborn hearing screening.

scholarly journals High incidence of cisplatin-induced ototoxicity in paediatric patients in the Western Cape, South Africa

2018 ◽  
Vol 2 ◽  
Author(s):  
Mukovhe Phanguphangu ◽  
Lebogang Ramma
Keyword(s):  
Hearing Loss ◽  
Otoacoustic Emissions ◽  
Negative Impact ◽  
Paediatric Oncology ◽  
Cancer Drug ◽  
Oncology Patients ◽  
Profound Hearing Loss ◽  
Distortion Product ◽  
High Incidence

Background: Fourteen million new cancer cases are reported annually, and up to 10% of those involve children below 15 years. Cisplatin, a commonly used anti-cancer drug for its high success rate, is associated with ototoxicity. Cisplatin-induced ototoxicity is characterised by permanent bilateral severe-to-profound hearing loss. Hearing loss, when occurring during childhood, can impact negatively communication development, scholastic performance and quality of life.Aim: To determine the incidence of cisplatin-induced ototoxicity in paediatric oncology.Setting: A retrospective records review of paediatric oncology patients who underwent cisplatin-based chemotherapy and had ototoxicity monitoring from January 2015 to December 2017 at a children’s hospital.Method: Data collected included demographic, cisplatin treatment and audiometric information. The data were analysed using descriptive and inferential statistics.Results: A total of 49 records meeting the inclusion criteria were reviewed. Ototoxic hearing loss was found in 39 (80%) of the patients whose records were reviewed and the majority (56%) presented with a bilateral moderate-to-severe sensorineural hearing loss. Distortion product otoacoustic emissions were absent in 32 (67%) patients. Cumulative dose (> 200 mg/m2) was associated with higher incidences of ototoxicity (odds ratio [OR]: 1.81; 95% confidence interval [CI]: 0.67–17.34; p = 0.044). Younger patients (< 10 years) had higher odds of developing ototoxicity, but this was not statistically significant (OR: 4.00; 95% CI: 0.82–19.46; p = 0.085).Conclusion: This study found a high incidence of cisplatin-induced ototoxicity in paediatric oncology patients. This is concerning because hearing loss during this age can have long-term negative impact on a child’s development and overall quality of life. Early identification of ototoxicity-induced hearing loss and appropriate intervention are highly recommended in this patient group.

Accuracy of velocity distortion product otoacoustic emissions for estimating mechanically based hearing loss

2009 ◽  
Vol 251 (1-2) ◽  
pp. 17-28 ◽  
Author(s):  
Diana Turcanu ◽  
Ernst Dalhoff ◽  
Marcus Müller ◽  
Hans-Peter Zenner ◽  
Anthony W. Gummer
Keyword(s):  
Hearing Loss ◽  
Otoacoustic Emissions ◽  
Distortion Product Otoacoustic Emissions ◽  
Distortion Product
Sign in / Sign up

Export Citation Format

Share Document